+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 6Years - 16Years
All Genders
ID06757504

Phase II Study of TTYP01 Tablets for Treating Children and Adolescents Aged 6 to Under 16 Years With Autism Spectrum Disorder

Led by Shanghai Auzone Biological Technology Co., Ltd. · Updated on 2025-05-14

150

Participants Needed

5

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, pharmacokinetics, and preliminary effects of TTYP01 tablets in children and adolescents with Autism Spectrum Disorder ASD. This multi-center, randomized, double-blind, placebo-controlled study aims to understand how different doses of TTYP01 work in participants aged 6 to under 16 years. The study will proceed in stages, starting with adolescents, then potentially including younger children after safety reviews by an independent monitoring board. Participants will be randomly assigned to one of three groups low-dose TTYP01, high-dose TTYP01, or placebo, with dosing based on body weight. The treatment is taken twice daily for 12 weeks, with doses adjusted according to safety and other data collected during the study. The trial includes careful monitoring, with safety and effectiveness reviews guiding continuation or changes. During the study, participants will undergo assessments at baseline and weeks 4, 8, and 12, including behavioral checklists, clinical global impressions, and social responsiveness scales. Blood samples will be collected to study drug levels and metabolism. Adverse events will be tracked throughout, and safety will be regularly reviewed. The total participation time is approximately 12 weeks of treatment with follow-up assessments.

CONDITIONS

Brief Title

Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD

Research Team

X

Xiaolong Hou

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here